Android app Apple app link

Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?

By Yahoo! Finance   |   1 month ago
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?

Black Diamond Therapeutics is developing MasterKey therapies targeting oncogenic mutations in cancer patients. Their lead drug, silevertinib, is being evaluated for EGFRm NSCLC and GBM.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.